Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.
Adherence
Adherence to medication
Distress
Myelofibrosis
Polycythemia Vera
Ruxolitinib
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
13 Mar 2024
13 Mar 2024
Historique:
received:
27
11
2023
accepted:
09
03
2024
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
aheadofprint
Résumé
Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence is scant. The Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319) included 189 ruxolitinib-treated patients. Patients completed the Adherence to Refills and Medications Scale (ARMS) and Distress Thermometer and Problem List (DTPL) at the earliest convenience, after registration in the study, and at later timepoints. At week-0, low adherence (ARMS > 14) and high distress (DT ≥ 4) were declared by 49.7% and 40.2% of patients, respectively. The main reason for low adherence was difficult ruxolitinib supply (49%), intentional (4.3%) and unintentional (46.7%) non-take. In multivariable regression analysis, low adherence was associated to male sex (p = 0.001), high distress (p < 0.001), and treatment duration ≥ 1 year (p = 0.03). Over time, rates of low adherence and high distress remained stable, but unintentional non-take decreased from 47.9% to 26.0% at week-48. MF patients with stable high adherence/low distress were more likely to obtain/maintain the spleen response at week-24. Low adherence to ruxolitinib represents an unmet clinical need that require a multifaceted approach, based on reason behind it (patients characteristics and treatment duration). Its recognition may help distinguishing patients who are truly refractory and those in need of therapy optimization.
Identifiants
pubmed: 38478023
doi: 10.1007/s00277-024-05704-0
pii: 10.1007/s00277-024-05704-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministero della Salute
ID : RC-2023-2778963
Informations de copyright
© 2024. The Author(s).
Références
Tefferi A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 96(1):145–162
doi: 10.1002/ajh.26050
pubmed: 33197049
Garmezy B, Schaefer JK, Mercer J, Talpaz M (2021) A provider’s guide to primary myelofibrosis: pathophysiology, diagnosis, and management. Vol. 45, Blood Reviews. Churchill Livingstone
Passamonti F, Mora B (2023) Myelofibrosis. Blood 141(16):1954–1970
doi: 10.1182/blood.2022017423
pubmed: 36416738
Passamonti F, Rumi E, Arcaini L, Castagnola C, Lunghi M, Bernasconi P et al (2005) Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer 104(5):1032–1036
doi: 10.1002/cncr.21297
pubmed: 16047334
Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874–1881
doi: 10.1038/leu.2013.163
pubmed: 23739289
pmcid: 3768558
Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M et al (2004) Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 117(10):755–761
doi: 10.1016/j.amjmed.2004.06.032
pubmed: 15541325
Vannucchi AM (2017) From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. Haematologica 102(1):18–29
doi: 10.3324/haematol.2015.129155
pubmed: 27884974
pmcid: 5210229
Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L et al (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30(8):1701–1707
doi: 10.1038/leu.2016.148
pubmed: 27211272
pmcid: 5399157
Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV et al (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):1–14
doi: 10.1186/s13045-017-0417-z
Verstovsek S, Gotlib J, Mesa RA, Vannucchi AM, Kiladjian JJ, Cervantes F et al (2017) Long-Term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and-II pooled analyses. J Hematol Oncol 10(1):1–6
doi: 10.1186/s13045-017-0527-7
Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P et al (2022) Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Lancet Haematol 9(7):e480–e492
doi: 10.1016/S2352-3026(22)00102-8
pubmed: 35597252
Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN et al (2020) Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Lancet Haematol 7(3):e226–e237
doi: 10.1016/S2352-3026(19)30207-8
pubmed: 31982039
pmcid: 8938906
Palandri F, Palumbo GA, Elli EM, Polverelli N, Benevolo G, Martino B et al (2021) Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer J 11(1):4
Tremblay D, Ronner L, Podoltsev N, Gotlib J, Heaney M, Kuykendall A et al (2021) Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database. Leuk Res 1(109):106629
doi: 10.1016/j.leukres.2021.106629
Palandri F, Palumbo GA, Bonifacio M, Tiribelli M, Benevolo G, Martino B et al (2017) Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget 8(45):79073–79086
doi: 10.18632/oncotarget.18674
pubmed: 29108288
pmcid: 5668021
Osterberg L, Blaschke T (2005) Adherence to Medication. N Engl J Med 353(5):487–497
doi: 10.1056/NEJMra050100
pubmed: 16079372
Guglielmelli P, Palandri F, Selleri C, Cilloni D, Mendicino F, Mazza P et al (2022) Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI). Leuk Lymphoma [Internet] 63(1):189–198
doi: 10.1080/10428194.2021.1969388
pubmed: 34521299
Kripalani S, Risser J, Gatti ME, Jacobson TA (2009) Development and evaluation of the adherence to refills and medications scale (ARMS) among low-literacy patients with chronic disease. Value Health 12(1):118–123
doi: 10.1111/j.1524-4733.2008.00400.x
pubmed: 19911444
Donovan KA, Grassi L, McGinty HL, Jacobsen PB (2014) Validation of the distress thermometer worldwide: state of the science. Psychooncology 23(3):241–250
doi: 10.1002/pon.3430
pubmed: 25160838
Efficace F, Cottone F, Yanez B, Kota V, Castagnetti F, Caocci G et al (2024) Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia. Cancer 130(2):287–299
Cutillo A, O’Hea E, Person SD, Lessard D, Harralson TL, Boudreaux E (2017) NCCN distress thermometer: cut off points and clinical utility. Oncol Nurs Forum 44(3):329
doi: 10.1188/17.ONF.329-336
pubmed: 29493167
pmcid: 5839660
Roth AJ, Kornblith AB, Batel-Copel L, Peabody E, Scher HI, Holland JC (1998) Rapid screening for psychologic distress in men with prostate carcinoma. Cancer 82(10):1904–1908
doi: 10.1002/(SICI)1097-0142(19980515)82:10<1904::AID-CNCR13>3.0.CO;2-X
pubmed: 9587123
Swerdlow SH, Campo E, Pileri SA, Lee Harris N, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375
doi: 10.1182/blood-2016-01-643569
pubmed: 26980727
pmcid: 4874220
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M et al (2010) Dynamic international prognostic scoring system (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 116(15):2857–2858
doi: 10.1182/blood-2010-06-293415
pubmed: 20947690
Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM et al (2013) Revised response criteria for myelofibrosis: international working group-myeloproliferative neoplasms research and treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122(8):1395–1398
doi: 10.1182/blood-2013-03-488098
pubmed: 23838352
pmcid: 4828070
Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S et al (2012) Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients With MPNs. J Clin Oncol 30(33):4098
doi: 10.1200/JCO.2012.42.3863
pubmed: 23071245
pmcid: 4872304
Lomper K, Chabowski M, Chudiak A, Białoszewski A, Dudek K, Jankowska-Polańska B (2018) Psychometric evaluation of the Polish version of the adherence to refills and medications scale (ARMS) in adults with hypertension. Patient Prefer Adherence 12:2661
doi: 10.2147/PPA.S185305
pubmed: 30587938
pmcid: 6296194
Bonsu KO, Young S, Lee T, Nguyen H, Chitsike RS (2022) Adherence to antithrombotic therapy for patients attending a multidisciplinary thrombosis service in Canada – a cross-sectional survey. Patient Prefer Adherence 16:1771–1780
doi: 10.2147/PPA.S367105
pubmed: 35923661
pmcid: 9339664
Alammari G, Alhazzani H, Alrajhi N, Sales I, Jamal A, Almigbal TH et al (2021) Validation of an Arabic version of the adherence to refills and medications scale (ARMS). Healthcare (Switzerland) 9(11):1430
Cramer JA, Rosenheck R, Kirk G, Krol W, Krystal J (2003) Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 6(5):566–573
doi: 10.1046/j.1524-4733.2003.65269.x
pubmed: 14627063
Langlais BT, Geyer H, Scherber R, Mesa RA, Dueck AC (2019) Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life? Leuk Lymphoma 60(2):402–408
doi: 10.1080/10428194.2018.1480768
pubmed: 30033837
Kosiorek HE, Scherber RM, Geyer HL, Verstovsek S, Langlais BT, Mazza GL et al (2022) Quality of life independently predicts overall survival in myelofibrosis: key insights from the controlled MyeloFibrosis study with oral Janus kinase inhibitor treatment (COMFORT)-I study. Br J Haematol 198(6):1065–1068
doi: 10.1111/bjh.18329
pubmed: 35751150
Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S et al (2007) The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 109(1):68–76
doi: 10.1002/cncr.22365
pubmed: 17123268
Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M et al (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol 96(10):1653–1665
doi: 10.1007/s00277-017-3082-y
pubmed: 28780729
pmcid: 5569657
Eghbali M, Akbari M, Seify K, Fakhrolmobasheri M, Heidarpour M, Roohafza H et al (2022) Evaluation of psychological distress, self-care, and medication adherence in association with hypertension control. Int J Hypertens 2022:7802792
Huang YM, Pecanac KE, Shiyanbola OO (2020) ‘Why am I not taking medications?’ Barriers and facilitators of diabetes medication adherence across different health literacy levels. Qual Health Res 30(14):2331–2342
doi: 10.1177/1049732320945296
pubmed: 32723206
Verweel L, Newman A, Michaelchuk W, Packham T, Goldstein R, Brooks D (2023) The effect of digital interventions on related health literacy and skills for individuals living with chronic diseases: A systematic review and meta-analysis. Int J Med Inform 1:177
Buyens G, van Balken M, Oliver K, Price R, Venegoni E, Lawler M et al (2023) Cancer literacy - Informing patients and implementing shared decision making. J Cancer Policy 1:35
Falagas ME, Karagiannis AKA, Nakouti T, Tansarli GS (2015) Compliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials. PLoS One 10(1):e0116207